Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG: Blinded (placebo)
DRUG: Open Label (Avatrombopag tablets)
DRUG: Blinded (Avatrombopoag tablets)

Sponsor

Eisai Inc.